StemCell Therapy

SANTA ANA, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body’s immune system through the development of natural killer (NK) cell therapies, today announced a collaboration with the Parkinson’s Foundation that will focus on ways to help accelerate NKGen’s clinical program using its novel autologous NK cell therapy (SNK01) for the treatment of advanced Parkinson’s disease (PD) through its network of clinical partners and donors.

View original post here:
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced...

VALNEVA

More here:
VALNEVA - Declaration of shares and voting rights: October 31, 2022

Leuven, BELGIUM, Boston, MA, US – November 4, 2022 – 7 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notification following the issuance of new shares pursuant to the Capital Commitment entered into with Negma Group.Oxurion received a transparency notification from Fidelity Management & Research Company LLC, indicating that by virtue of a downward passive crossing of a threshold, its 3,128,819 common shares have crossed below the 5% threshold.

The rest is here:
Oxurion Receives Transparency Notification from Fidelity Management & Research Company LLC

Negma Group has converted 120 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.

Read the original here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

Bagsværd, Denmark, 4 November 2022 – This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Link:
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Webcast replay available at www.glpg.com

Read this article:
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:

Link:
Fate Therapeutics to Present at Upcoming Investor Conferences

NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022

See the original post:
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update

- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis stage 4 at baseline (putative F4); excluding these patients resulted in higher histological response rates in the patients with F2-F3 fibrosis than previously reported -

Read the original here:
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022

Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting, including evidence that:

Follow this link:
New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

CAMBRIDGE, Mass., Nov. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today presented additional interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis in collaboration with Regeneron Pharmaceuticals. Results were presented in a Late-Breaking Science oral presentation at the American Heart Association (AHA) Scientific Sessions 2022, held November 5 – 7 in Chicago, Illinois.

See original here:
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the...

Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster

Read the original post:
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be...

– Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals –

See the rest here:
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus...

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30 and 90 Days Following Hospital Discharge Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30 and 90 Days Following Hospital Discharge

Read this article:
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 7, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in November:

View post:
argenx to Present at Upcoming Investor Conferences

GÉNOMIQUE | GÉNÉTIQUE | R&D | TESTS DE DIAGNOSTIC

Visit link:
Genomic Vision et Cambridge Consultants, filiale de Capgemini, annoncent le développement d'une plateforme technologique innovante dédiée à...

Read more from the original source:
Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma

REGULATED INFORMATION

Here is the original post:
Bone Therapeutics provides Third Quarter 2022 Business Update

Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value

Read the original here:
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program

Excerpt from:
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022